{"id":743843,"date":"2013-02-20T07:00:00","date_gmt":"2013-02-20T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/"},"modified":"2023-03-22T00:04:41","modified_gmt":"2023-03-22T04:04:41","slug":"merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/","title":{"rendered":"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement"},"content":{"rendered":"<p>\n      Merck, (NYSE: MRK) known as MSD outside the United States and Canada,<br \/>\n      and Samsung Bioepis Co., Ltd., entered into an agreement to develop and<br \/>\n      commercialize multiple pre-specified and undisclosed biosimilar<br \/>\n      candidates.\n    <\/p>\n<p>\n      \u201cThe combination of Merck\u2019s global commercial presence with Samsung<br \/>\n      Bioepis\u2019 biologic development and manufacturing capabilities positions<br \/>\n      the two companies well to increase access to biosimilars to improve<br \/>\n      human health,\u201d said Rich Murray, Ph.D., senior vice president, biologics<br \/>\n      and vaccines research, Merck Research Laboratories. \u201cWe look forward to<br \/>\n      this collaboration and its potential to complement our expanding<br \/>\n      internal biologics portfolio.\u201d\n    <\/p>\n<p>\n      Under the agreement, Samsung Bioepis will be responsible for preclinical<br \/>\n      and clinical development, process development and manufacturing,<br \/>\n      clinical trials and registration. Merck will be responsible for<br \/>\n      commercialization. Samsung Bioepis will receive an upfront payment from<br \/>\n      Merck, product supply income and will be eligible for additional<br \/>\n      payments associated with pre-specified clinical and regulatory<br \/>\n      milestones. Further financial terms were not disclosed.\n    <\/p>\n<p>\n      \u201cSamsung Bioepis has been building\u00a0the capabilities needed to develop<br \/>\n      high-quality biosimilars,\u201d said Christopher Hansung Ko, Ph.D., CEO of<br \/>\n      Samsung Bioepis. \u201cWith this development and\u00a0commercialization agreement,<br \/>\n      Samsung takes a significant step toward becoming a major player in the<br \/>\n      biopharmaceutical industry.\u201d\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50570151&#038;lan=en-US&#038;anchor=www.Merck.com&#038;index=1&#038;md5=5d0659bd2cc6b91cc40dd0a8cf08cb96\">www.Merck.com<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>About Samsung Bioepis<\/b>\n    <\/p>\n<p>\n      Samsung Bioepis, a joint venture between Samsung Biologics and Biogen<br \/>\n      Idec, aims to develop affordable and high-quality biopharmaceutical and<br \/>\n      biosimilar products. For more information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.samsungbioepis.com&#038;esheet=50570151&#038;lan=en-US&#038;anchor=www.samsungbioepis.com&#038;index=2&#038;md5=021c37a561b1d4bb23e4af61f98fd061\">www.samsungbioepis.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50570151&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=3&#038;md5=0398d3dd729aa87f5c7775a0557007b5\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130220005579r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20130220005579\/en\/\">http:\/\/www.businesswire.com\/multimedia\/home\/20130220005579\/en\/<\/a><\/span><\/p>\n<p>       Merck Media Relations:<br \/>Ronald Rogers, 908-423-6449<br \/>or<br \/>Merck        Investor Relations:<br \/>Justin Holko, 908-423-5088<br \/>or<br \/>Samsung        Bioepis:<br \/>HongSeok Ji, +82-32-455-6102     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. \u201cThe combination of Merck\u2019s global commercial presence with Samsung Bioepis\u2019 biologic development and manufacturing capabilities positions the two companies well to increase access to biosimilars to improve human health,\u201d said Rich Murray, Ph.D., senior vice president, biologics and vaccines research, Merck Research Laboratories. \u201cWe look forward to this collaboration and its potential to complement our expanding internal biologics portfolio.\u201d Under the agreement, Samsung Bioepis will be responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration. Merck will be responsible for commercialization. Samsung Bioepis will receive an upfront payment from Merck, product supply income and will be eligible for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-743843","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. \u201cThe combination of Merck\u2019s global commercial presence with Samsung Bioepis\u2019 biologic development and manufacturing capabilities positions the two companies well to increase access to biosimilars to improve human health,\u201d said Rich Murray, Ph.D., senior vice president, biologics and vaccines research, Merck Research Laboratories. \u201cWe look forward to this collaboration and its potential to complement our expanding internal biologics portfolio.\u201d Under the agreement, Samsung Bioepis will be responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration. Merck will be responsible for commercialization. Samsung Bioepis will receive an upfront payment from Merck, product supply income and will be eligible for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/\",\"name\":\"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-02-20T07:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement - Merck.com","og_description":"Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. \u201cThe combination of Merck\u2019s global commercial presence with Samsung Bioepis\u2019 biologic development and manufacturing capabilities positions the two companies well to increase access to biosimilars to improve human health,\u201d said Rich Murray, Ph.D., senior vice president, biologics and vaccines research, Merck Research Laboratories. \u201cWe look forward to this collaboration and its potential to complement our expanding internal biologics portfolio.\u201d Under the agreement, Samsung Bioepis will be responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration. Merck will be responsible for commercialization. Samsung Bioepis will receive an upfront payment from Merck, product supply income and will be eligible for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:41+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/","name":"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx","datePublished":"2013-02-20T07:00:00+00:00","dateModified":"2023-03-22T04:04:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130220005579r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-samsung-bioepis-enter-biosimilars-development-and-commercialization-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f0b64bb9-036a-4962-93ca-656bcf72f241","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743843\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743843"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}